Mirum Pharmaceuticals 株価情報 (NASDAQ: MIRM)

最新ニュース Mirum Pharmaceuticals (NASDAQ:MIRM) 株価情報

Mirum Pharmaceuticals

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals Inc

Macro Economic Events

News

Economics

U.S. Treasury's Bessent Says Banking Supervisors Should Analyze Supplementary Leverage Restrictions; Will Use FSOC To Drive Regulatory Change; Banks Have Been Weighed Down By Unduly Burdensome Regulatory Requirements, Broken Supervisory Culture

Morgan Stanley analyst Betsy Graseck maintains Northern Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRS#NASDAQ">NTRS</a>) with a Equal-Weight and lowers the price target from $138 to $136.

Price Target

Analyst Ratings

NTRS

Morgan Stanley Maintains Equal-Weight on Northern Trust, Lowers Price Target to $136

All three major indices remain in the red midday Thursday, after trimming earlier losses which saw the Dow Jones down more than 600 points at session lows. The major averages lost more than 2% this week as U.S. tariffs on Canadian, Mexican and Chinese imports took effect and trade partners responded with retaliatory <a href="https://www.benzinga.com/markets/forex/25/03/44161314/us-stocks-likely-to-open-lower-after-wednesdays-blip-be-patient-but-be-ready-to-act-says-analyst-as-market-uncertainties-can-create-opportunities">levies on U.S. goods. </a>
Investors awaited clarity on President Donald Trump&#8217;s trade policies after Commerce Secretary Howard Lutnick told CNBC the president is likely to allow exemptions for more than just carmakers.
Lutnick also stated that Mexico and Canada might avoid reciprocal tariffs planned for April if they make sufficient progress in curbing the flow of fentanyl into the U.S. Following Lutnick&#8217;s remarks, stocks rebounded from their lows during Thursday&#8217;s trading session.
Read Next: <a href="https://www.benzinga.com/news/econ-s/25/03/44143666/us-services-sector-unexpectedly-expands-in-february-despite-slowing-job-growth">US Services Sector Unexpectedly Expands In February Despite Slowing Job Growth</a>
WTI crude oil futures <a href="https://www.benzinga.com/25/03/44168987/oil-prices-hit-multi-year-lows">continued to slide</a> at multi-year lows as trade policies and OPEC+ production increases weighed on the market. The United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), tracking WTI futures contracts, fell 0.81%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) traded above the $90,000 level, up more than 7% for the week, as investors anticipated announcements from Trump&#8217;s crypto summit to be held at the White House on Friday.
<h1 class="wp-block-heading">Thursday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,336.60</td>
<td>-1.04%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,791.25</td>
<td>-0.88%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,808.25</td>
<td>-0.46%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,093.92</td>
<td>-0.36%</td>
</tr>
</tbody>
</table>
</figure>
According to Benzinga Pro data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.89% to $577.88.</li>
<li>The SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was down 0.49% at $428.32.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) dropped 1.35% to $495.25.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.62% to $207.17.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) slid 1.31% to $208.65.</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)&nbsp;rebounded 0.14% to $85.83.&nbsp;</li>
</ul>
<h1 class="wp-block-heading">Thursday's Stock Movers&nbsp;</h1>
Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) <a href="https://www.benzinga.com/25/03/44166971/marvell-technology-stock-is-tumbling-thursday-whats-going-on">shares dropped </a>Thursday after the chipmaker issued mixed first-quarter guidance, dragging other chip-related stocks like NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) lower as well.
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>Grindr Inc.&nbsp; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>)</li>
<li>LendingTree, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>)</li>
<li>MongoDB, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>)</li>
<li>Rigetti Computing, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>)</li>
<li>Marvell Technology, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>)</li>
<li>Zscaler, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) <a href="https://www.benzinga.com/quote/zs" target="_blank" rel="noreferrer noopener"></a><a href="https://www.benzinga.com/quote/zs" target="_blank" rel="noreferrer noopener"></a></li>
<li>Victorias Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>)</li>
<li>JD.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)</li>
<li>BJ&#8217;s Wholesale Club Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>)</li>
<li>Burlington Stores, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>)</li>
<li>Macy&#8217;s Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>)</li>
</ul>
Companies reporting after Thursday's closing bell include:&nbsp;
<ul>
<li>Costco Wholesale Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>)</li>
<li>Hewlett Packard Enterprise Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>)</li>
<li>Funko, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>)</li>
<li>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</li>
<li>Reliance Global Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>)</li>
<li>Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>)</li>
</ul>
Read Next:<a href="https://www.benzinga.com/general/social-media/25/03/44098232/markets-tank-after-trump-confirms-more-tariffs-heres-what-wall-street-is-saying" target="_blank" rel="noreferrer noopener">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/03/44098232/markets-tank-after-trump-confirms-more-tariffs-heres-what-wall-street-is-saying" target="_blank" rel="noreferrer noopener">Markets Tank After Trump Confirms More Tariffs: Here&#8217;s What Wall Street Is Saying</a></li>
</ul>
Image: Shutterstock

Equities

Market Summary

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Global

Markets

Movers

ETFs

General

$BTC

AVGO

BURL

COST

SPDR Dow Jones Industrial Average ETF Trust

FNKO

GRND

MRVL

NVDA

RELI

RGTI

SERV

TREE

VSCO

Select Sector SPDR-Consumer Discretionary

Trade Turmoil, Oil Slides: What's Driving Markets Thursday?

WIIM

APPS

BTDR

BTOG

CFLT

Core Scientific, Inc. - Class A Common Stock

CORZ

DOCU

ESTC

HUBS

KVYO

MNDY

NTNX

NVNI

ORCL

PLTR

PRCH

RBRK

RIOT

TEAM

Shares of software companies are trading lower amid overall market weakness. The industry may be falling amid sympathy with MongoDB after the company issued weak FY26 guidance.

U.S. Treasury's Bessent Says Refocusing Banking Supervision Does Not Mean Consolidation Of Agencies, But Coordination Via Treasury

Politics

U.S. Treasury's Bessent Says President Trump's Tariff Policies Have Begun Process Of Reorienting Our International Economic Relations

On Wednesday, Denali Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNLI#NASDAQ">DNLI</a>) provided an update on Regimen G of the Phase 2/3 HEALEY ALS Platform Trial of DNL343 for <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">amyotrophic lateral sclerosis</a>.
The company said that further analyses did not demonstrate a treatment effect on neurofilament light (NfL), a biomarker of neuronal damage, over the 24-week, double-blind period and in a subset of participants that completed an additional 28 weeks in the open-label active treatment extension.
The company plans to discontinue the active treatment extension in Regimen, according to an SEC <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1714899/000171489925000072/dnli-20250305.htm" target="_blank" rel="noreferrer noopener">filing</a>. Overall, DNL343 was found to be safe and well-tolerated.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42856965/denali-therapeutics-amyotrophic-lateral-sclerosis-misses-pivotal-trial-but-analyst-says-it-was-expected" rel="noreferrer noopener">Denali Therapeutics&#8217; Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected</a>
Data from Regimen G will be presented at a future medical meeting. Denali intends to assess potential future development opportunities for DNL343.
In January, Denali revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating DNL343 for amyotrophic lateral sclerosis.
Compared to placebo, the study did not meet the primary endpoint of efficacy in <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42856965/denali-therapeutics-amyotrophic-lateral-sclerosis-misses-pivotal-trial-but-analyst-says-it-was-expected" rel="noreferrer noopener">slowing disease progression</a>.
William Blair analysts found the update &#8220;disappointing,&#8221; but largely expected following the previous update on the failed study. The analyst sees little impact on fair value estimates, which have been slightly lowered from $32/share to $30/share.
Analyst Sarah Schram believes the key investment focus will be on 2025 updates regarding the FDA&#8217;s accelerated approval application for Tividenofusp alfa in Hunter syndrome, with potential approval by late 2025 or early 2026.
Schram also expects clarity on the regulatory process for DNL126 in Sanfilippo syndrome, likely following a similar path as Tividenofusp.
Additionally, the company plans to expand its transport vehicle platform, aiming to move one or two new treatments into clinical trials each year for the next three years.
Based on biomarker and clinical data, Schram sees Tividenofusp as a leading treatment for Hunter syndrome. She believes the market is undervaluing the drug and the company's platform. This could also be used for common diseases like Parkinson's and Alzheimer's.
William Blair reiterates the Outperform rating on Denali and remains a buyer on the recent weakness.
Price Action: Denali stock is down 2.64% at $15.87 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44169392/kroger-beats-q4-earnings-estimates-amid-leadership-shakeup" target="_blank" rel="noreferrer noopener">Kroger Q4 Earnings: EPS Beat, Sales Miss, Soft Outlook And More</a></li>
</ul>

Analyst Color

Biotech

Health Care

DNLI

Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback

SBUX

Starbucks shares are trading lower following a report suggesting the company needed to reorganize to make leaders more accountable for financial and operational improvements. The stock may also be falling amid a drop in coffee production.

Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) with a Overweight and raises the price target from $42 to $52.

Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $52

PINS

Pinterest CEO Bill Ready Says About 15% Of Our Code Base Is Now Generated Through AI

Morgan Stanley analyst Erik Woodring maintains Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) with a Underweight and lowers the price target from $3.9 to $3.8.

CRCT

Morgan Stanley Maintains Underweight on Cricut, Lowers Price Target to $3.8

GEVO

Gevo Announces That It Will Delay The Issuance Of Its Q4 And FY24 Earnings Release And Investor Conference Call Previously Scheduled for March 6, 2025

Atlantic International Corp. ("Atlantic") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATLN#NASDAQ">ATLN</a>), a leading provider of strategic staffing, outsourced services and workforce solutions, today announced that its subsidiary Lyneer Staffing Solutions ("Lyneer") has secured a significant contract renewal with a premier North American baking company in Northern California.
The renewed partnership includes an expansion to additional locations, positioning Lyneer to capture approximately $10 million in spending. This expanded relationship underscores Lyneer's proven track record of delivering high-quality workforce solutions tailored to the specialized needs of the food production industry.

Contracts

ATLN

Atlantic International Corp Announces Its Subsidiary Lyneer Staffing Solutions Has Secured A Contract Renewal With A Premier North American Baking Company In Northern California

Investors with a lot of money to spend have taken a bearish stance on Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ORCL, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 39 uncommon options trades for Oracle.
This isn't normal.
The overall sentiment of these big-money traders is split between 33% bullish and 51%, bearish.
Out of all of the special options we uncovered, 21 are puts, for a total amount of $2,070,633, and 18 are calls, for a total amount of $938,791.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $95.0 to $180.0 for Oracle during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Oracle's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Oracle's significant trades, within a strike price range of $95.0 to $180.0, over the past month.
<h3>Oracle Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741280492_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORCL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.85</td>
<td>$10.65</td>
<td>$10.9</td>
<td>$135.00</td>
<td>$545.0K</td>
<td>420</td>
<td align="right">500</td>
</tr>
<tr>
<td>ORCL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$21.7</td>
<td>$21.25</td>
<td>$21.75</td>
<td>$170.00</td>
<td>$326.2K</td>
<td>3.0K</td>
<td align="right">150</td>
</tr>
<tr>
<td>ORCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$14.0</td>
<td>$13.85</td>
<td>$13.85</td>
<td>$160.00</td>
<td>$138.5K</td>
<td>1.7K</td>
<td align="right">3</td>
</tr>
<tr>
<td>ORCL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/07/25</td>
<td>$6.5</td>
<td>$6.25</td>
<td>$6.5</td>
<td>$162.50</td>
<td>$125.4K</td>
<td>1.0K</td>
<td align="right">211</td>
</tr>
<tr>
<td>ORCL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.88</td>
<td>$1.85</td>
<td>$1.88</td>
<td>$135.00</td>
<td>$112.4K</td>
<td>14.7K</td>
<td align="right">608</td>
</tr>
</tbody>
</table>

<h3>About Oracle</h3>
Oracle provides enterprise applications and infrastructure offerings around the world through a variety of flexible IT deployment models, including on-premises, cloud-based, and hybrid. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system, which is commonly used for running online transaction processing and data warehousing workloads. Besides database systems, Oracle also sells enterprise resource planning, or ERP, customer relationship management, or CRM, and human capital management, or HCM, applications. Today, Oracle has more than 159,000 full-time employees in over 170 countries.
<h3>Current Position of Oracle</h3>
<ul>
<li>With a trading volume of 3,908,152, the price of ORCL is down by -4.12%, reaching $154.91.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 4 days from now.</li>
</ul>
<h3>What The Experts Say On Oracle</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $220.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Guggenheim downgraded its rating to Buy, setting a price target of $220. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Oracle with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

What the Options Market Tells Us About Oracle

Victorias Secret &amp; Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) shares are trading lower on Thursday after the company issued first-quarter and FY25 sales <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44165610/victorias-secret-delivers-solid-q4-results-but-ceo-warns-of-near-term-headwinds" rel="noreferrer noopener">guidance below estimates.</a>
Revenue rose&nbsp;1%&nbsp;year over year to&nbsp;$2.11&nbsp;billion, beating the consensus of&nbsp;$2.09 billion, and adjusted EPS&nbsp;of&nbsp;$2.60 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat&nbsp;the consensus of&nbsp;$2.30</a>.
The company expects&nbsp;net sales of&nbsp;$1.30 billion – $1.33 billion vs. consensus of $1.39 billion&nbsp;for the&nbsp;first quarter and $6.2 billion – $6.3 billion&nbsp;vs. <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus of $6.34 billion for FY25</a>.
J.P. Morgan analyst Matthew R. Boss lowered the price forecast from $43.00 to<a target="_blank" href="https://www.benzinga.com/quote/VSCO/analyst-ratings" rel="noreferrer noopener"> $35.00, with a Neutral rating</a>.
The analyst writes that for the balance of the year, management&#8217;s full-year guidance implies that the second quarter-fourth quarter revenues will accelerate to +1% growth on average (&gt; first quarter&#8217;s -4% to -2% guidance range).
Boss notes that second quarter-fourth quarter same-store-sales comparisons on a 1-year basis are sequentially harder versus first quarter by 670bps.
The analyst writes that after recent leadership changes in the C-Suite and merchandising/product functions, VSCO is starting to see topline growth across both the VS and PINK brands.
Although the turnaround is still in the early stages, there is a multi-year opportunity to drive higher full-price selling, expand gross margins, and leverage SG&amp;A on sustained revenue growth, ultimately improving operating margins, says the analyst.
The analyst cut the FY25 EPS estimates to $2.30 from $2.74 (vs. Street $2.80) and expects FY26 EPS of $2.40 (vs. Street $3.14).
Other analyst&#8217;s price forecast revisions include:
<ul>
<li>Wells Fargo analyst Ike Boruchow cut the price forecast from $40 to $25, while keeping an Equal-Weight rating.</li>
<li>BMO Capital analyst Simeon Siegel reiterated an Outperform rating and lowered the price forecast from $46 to $31.</li>
<li>Telsey Advisory Group analyst Dana Telsey kept a Market Perform rating and slashed the price forecast from $40 to $24.</li>
</ul>
Price Action: VSCO shares are down 2.96% at $21.55 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44146094/wall-street-awaits-trumps-tariff-decision-digests-mixed-economic-data-whats-driving-markets-wednesday" target="_blank" rel="noreferrer noopener">Wall Street Awaits Trump&#8217;s Tariff Decision, Digests Mixed Economic Data: What&#8217;s Driving Markets Wednesday?</a></li>
</ul>
Photo via Shutterstock.

Large Cap

Reiteration

Trading Ideas

Victoria's Secret Turnaround In Progress But Challenges Remain: Analyst Lowers Forecast

Investors with a lot of money to spend have taken a bearish stance on Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ADBE, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 29 uncommon options trades for Adobe.
This isn't normal.
The overall sentiment of these big-money traders is split between 34% bullish and 55%, bearish.
Out of all of the special options we uncovered, 14 are puts, for a total amount of $788,618, and 15 are calls, for a total amount of $684,345.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $220.0 and $560.0 for Adobe, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Adobe's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Adobe's substantial trades, within a strike price spectrum from $220.0 to $560.0 over the preceding 30 days.
<h3>Adobe 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741280487_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$10.05</td>
<td>$9.75</td>
<td>$9.93</td>
<td>$420.00</td>
<td>$148.9K</td>
<td>4.1K</td>
<td align="right">150</td>
</tr>
<tr>
<td>ADBE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$250.5</td>
<td>$247.75</td>
<td>$250.5</td>
<td>$220.00</td>
<td>$125.2K</td>
<td>15</td>
<td align="right">0</td>
</tr>
<tr>
<td>ADBE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/04/25</td>
<td>$20.15</td>
<td>$18.8</td>
<td>$20.15</td>
<td>$450.00</td>
<td>$100.7K</td>
<td>73</td>
<td align="right">0</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$51.0</td>
<td>$50.9</td>
<td>$51.0</td>
<td>$475.00</td>
<td>$76.5K</td>
<td>58</td>
<td align="right">0</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/14/25</td>
<td>$48.3</td>
<td>$47.8</td>
<td>$48.3</td>
<td>$490.00</td>
<td>$72.4K</td>
<td>39</td>
<td align="right">15</td>
</tr>
</tbody>
</table>

<h3>About Adobe</h3>
Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).
Having examined the options trading patterns of Adobe, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Adobe</h3>
<ul>
<li>Currently trading with a volume of 674,542, the ADBE's price is down by -0.46%, now at $449.18. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 6 days.</li>
</ul>
<h3>Expert Opinions on Adobe</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $552.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for Adobe, targeting a price of $515. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $590. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Adobe, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

ADBE

Market Whales and Their Recent Bets on ADBE Options

Whales with a lot of money to spend have taken a noticeably bearish stance on Philip Morris Intl.
Looking at options history for Philip Morris Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 20% of the investors opened trades with bullish expectations and 40% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $238,106 and 5, calls, for a total amount of $336,708.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $85.0 to $170.0 for Philip Morris Intl during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Philip Morris Intl options trades today is 1068.0 with a total volume of 324.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Philip Morris Intl's big money trades within a strike price range of $85.0 to $170.0 over the last 30 days.
<h3>Philip Morris Intl 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741280482_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$7.8</td>
<td>$7.7</td>
<td>$7.8</td>
<td>$160.00</td>
<td>$125.5K</td>
<td>3.4K</td>
<td align="right">3</td>
</tr>
<tr>
<td>PM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/07/25</td>
<td>$68.9</td>
<td>$68.2</td>
<td>$68.54</td>
<td>$85.00</td>
<td>$54.8K</td>
<td>8</td>
<td align="right">40</td>
</tr>
<tr>
<td>PM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/07/25</td>
<td>$68.9</td>
<td>$67.8</td>
<td>$68.37</td>
<td>$85.00</td>
<td>$54.6K</td>
<td>8</td>
<td align="right">16</td>
</tr>
<tr>
<td>PM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$18.3</td>
<td>$18.0</td>
<td>$18.21</td>
<td>$170.00</td>
<td>$50.9K</td>
<td>191</td>
<td align="right">56</td>
</tr>
<tr>
<td>PM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/07/25</td>
<td>$63.9</td>
<td>$63.2</td>
<td>$63.55</td>
<td>$90.00</td>
<td>$50.8K</td>
<td>8</td>
<td align="right">40</td>
</tr>
</tbody>
</table>

<h3>About Philip Morris Intl</h3>
Created from the international operations of Altria in 2008, Philip Morris International sells cigarettes and reduced-risk products, including heatsticks, vapes, and oral nicotine offerings primarily outside of the US. With the 2023 acquisition of Swedish Match, a leading manufacturer of traditional oral tobacco products and nicotine pouches primarily in the US and Scandinavia, PMI has not only diversified away from smokeable products but also gained a toehold into the US to sell its iQOS heated tobacco product.
After a thorough review of the options trading surrounding Philip Morris Intl, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Philip Morris Intl</h3>
<ul>
<li>Currently trading with a volume of 1,434,830, the PM's price is up by 0.01%, now at $153.16. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 48 days.</li>
</ul>
<h3>What The Experts Say On Philip Morris Intl</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $153.75.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Stifel persists with their Buy rating on Philip Morris Intl, maintaining a target price of $160. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Philip Morris Intl, targeting a price of $175. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Sell rating on Philip Morris Intl with a target price of $120. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Philip Morris Intl, targeting a price of $160. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Philip Morris Intl options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Smart Money Is Betting Big In Philip Morris Intl Options

Kevin O&#8217;Leary has a sharp message for consumers drowning in credit card debt: take a hard look at your closet. According to the <a href="https://www.benzinga.com/startups/24/09/40839130/were-looking-for-a-real-a-e-and-youre-in-kevin-oleary-on-how-he-got-his-infamous-shark-tank-role">&#8220;Shark Tank&#8221; investor</a>, most people only wear about 25% of what they own, while the other 75% is just &#8220;dead money.&#8221;
<h2 class="wp-block-heading">The Cost of Unworn Clothes</h2>
&#8220;One of the reasons I&#8217;m an investor in almost all the credit card companies is they make a lot of money on a predatory basis,&#8221; O&#8217;Leary said in a recent <a href="https://x.com/kevinolearytv/status/1896225233457005037">video</a>. &#8220;They get you to spend on things you don&#8217;t need. Go into your closet and look at your shoes, your jeans, your T-shirts, and your suits. Just there. Everybody has those, men or women. You&#8217;re only wearing 25% of them.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Credit card companies love getting you to buy things you don't need. Go check your closet—you're only wearing 25% of what's in there. That other 75%? Dead money. If you'd invested that cash instead, you'd be sitting on millions at retirement. But hey, enjoy those sneakers. <a href="https://t.co/6w6wNg8Rd3">pic.twitter.com/6w6wNg8Rd3</a>
&mdash; Kevin O&#39;Leary aka Mr. Wonderful (@kevinolearytv) <a href="https://twitter.com/kevinolearytv/status/1896225233457005037?ref_src=twsrc%5Etfw">March 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
<li>The average 401(k) balance soars to a record-breaking high – <a href="https://www.benzinga.com/money/average-401k-balances-soars-to-record-high">Here's how to know if your nest egg is keeping pace.</a></li>
</ul>
Instead of letting money sit in unworn clothing, O&#8217;Leary argues that investing even a fraction of that cash could make a <a href="https://www.benzinga.com/news/25/03/44081583/my-mom-was-not-a-stock-analyst-just-a-working-woman-when-she-passed-she-was-rich-kevin-oleary-reveals-her-lifelong-process-you-can-copy">huge difference in the long run</a>. &#8220;That money is dead. It could have made eight percent a year. And you do that for 60 years, you have nothing to speak of,&#8221; he warned.
<h2 class="wp-block-heading">Americans Are Drowning in Credit Card Debt</h2>
O&#8217;Leary&#8217;s concerns come at a time when credit card debt in the U.S. has hit an all-time high. By the end of the fourth quarter of 2024, <a href="https://www.benzinga.com/news/25/02/43888952/americans-owe-a-record-1-21-trillion-in-credit-card-debt-expert-warns-theres-no-end-in-sight">Americans owed a record $1.21 trillion</a> on their credit cards, up $45 billion from the previous quarter. Holiday spending played a major role, with consumers shelling out $702 billion during the season, <a href="https://fred.stlouisfed.org/series/RSXFSN">according to the Federal Reserve Bank of St. Louis</a>.
Trending: Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.
At the same time, more Americans are falling behind on their payments. Over 10.9% of credit card accounts were more than 90 days delinquent in the third quarter of 2024, the highest rate since 2012. LendingTree Chief Credit Analyst Matt Schulz <a href="https://www.nbcnews.com/business/personal-finance/credit-card-debt-hit-record-1point21-trillion-no-one-surprised-rcna192128">explained</a> the reason behind the rising debt: &#8220;Stubborn inflation has shrunk a lot of Americans&#8217; financial margin for error from slim to about none, forcing people to lean more heavily on credit card debt.&#8221;
Adding to the strain, the average credit card interest rate has climbed above 20%, making it even harder for those carrying a balance to pay off their debt.
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
<h2 class="wp-block-heading">O&#8217;Leary's Simple Investment Strategy</h2>
O&#8217;Leary believes the cycle of overspending and accumulating debt is setting people up for financial failure. Instead, he suggests a simple alternative: &#8220;If all you did was take 15% of your salary and put it into, you know, a very simple portfolio, just buy the index, the S&amp;P, you&#8217;d have a million and a half dollars when you retire.&#8221;
With the average American salary at $69,000, setting aside 15%—or about $10,350 per year—into an S&amp;P 500 index fund could <a href="https://www.benzinga.com/money/smartasset">build substantial wealth over time</a>.
Read Next:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li><a href="https://www.benzinga.com/money/suze-orman-retirement-bucket">&#8216;Which Bucket Do I Draw From First?&#8217; Suze Orman Explains To 67-Year-Old The Best Order For Tapping Into Her Retirement Accounts</a></li>
</ul>

Kevin O'Leary Says Your Closet Is Full Of 'Dead Money'—Invest Instead, And You Could Retire With Millions

<a href="https://www.wsj.com/business/hospitality/starbucks-ceo-tells-workers-to-step-it-up-after-layoffs-3fdba9f3" title="https://www.wsj.com/business/hospitality/starbucks-ceo-tells-workers-to-step-it-up-after-layoffs-3fdba9f3">https://www.wsj.com/business/hospitality/starbucks-ceo-tells-workers-to-step-it-up-after-layoffs-3fdba9f3</a>

Management

Reported March 5, 2025: "Starbucks CEO Tells Workers To Step It Up After Layoffs; Brian Niccol Says Coffee Chain's Turnaround Hinges On Greater Accountability; 'We Own Whether Or Not This Place Grows'" - WSJ

Mexico President Claudia Sheinbaum Says Agreement To Pause Tariffs On Mexico's USMCA-Compliant Goods Is Until April 2; We Will Also Work Together On Crossing Of Guns Into Mexico

Press Releases

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025

Mirum's CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Comments

Mirum Pharmaceuticals

ニュース

最新ニュース Mirum Pharmaceuticals (NASDAQ:MIRM) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル